CMQCC Releases Statement on Application of the ARRIVE Trial

Following the publication of “A Randomized Trial of Induction Versus Expectant Management (ARRIVE)” study in the New England Journal of Medicine last week, CMQCC’s Medical Director Elliott Main and the leadership team have released the attached statement about the application of the ARRIVE trial into practice. 

CMQCC cautions that if a hospital’s induction guidelines are changed to allow for elective inductions at 39 weeks, strict guidelines for defining failed induction and guidelines for management of active phase and fetal monitoring abnormalities should be adopted simultaneously. If labor guidelines and definitions for failed induction similar to those in the study hospitals are not adopted, it is very likely cesarean rates will rise significantly. This can be followed in CMQCC's Maternal Data Center. Please read the full CMQCC statement here